ATE188036T1 - Glykoalkaloide - Google Patents

Glykoalkaloide

Info

Publication number
ATE188036T1
ATE188036T1 AT91901984T AT91901984T ATE188036T1 AT E188036 T1 ATE188036 T1 AT E188036T1 AT 91901984 T AT91901984 T AT 91901984T AT 91901984 T AT91901984 T AT 91901984T AT E188036 T1 ATE188036 T1 AT E188036T1
Authority
AT
Austria
Prior art keywords
cells
abnormal
cellular
removal
normal
Prior art date
Application number
AT91901984T
Other languages
English (en)
Inventor
Bill Elliott Cham
Brian Daunter
Original Assignee
Cura Nominees Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cura Nominees Pty Ltd filed Critical Cura Nominees Pty Ltd
Application granted granted Critical
Publication of ATE188036T1 publication Critical patent/ATE188036T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/81Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0042Nitrogen only
    • C07J71/0052Nitrogen only at position 16(17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036Nitrogen-containing hetero ring
    • C07J71/0057Nitrogen and oxygen
    • C07J71/0068Nitrogen and oxygen at position 16(17)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/14Topical contraceptives and spermacides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT91901984T 1990-01-18 1991-01-18 Glykoalkaloide ATE188036T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ824390 1990-01-18
PCT/AU1991/000020 WO1991010743A1 (en) 1990-01-18 1991-01-18 Glycoalkaloids

Publications (1)

Publication Number Publication Date
ATE188036T1 true ATE188036T1 (de) 2000-01-15

Family

ID=3774458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901984T ATE188036T1 (de) 1990-01-18 1991-01-18 Glykoalkaloide

Country Status (11)

Country Link
US (1) US5958770A (de)
EP (1) EP0515386B1 (de)
JP (1) JP3168542B2 (de)
KR (1) KR100213805B1 (de)
AT (1) ATE188036T1 (de)
AU (1) AU654474B2 (de)
BR (1) BR9105952A (de)
CA (1) CA2073855C (de)
DE (1) DE69131861T2 (de)
SG (1) SG50585A1 (de)
WO (1) WO1991010743A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5081593A (en) * 1992-08-21 1994-03-15 New York University Aminofurostenes, compositions, and methods of use
GB9618119D0 (en) 1996-08-30 1996-10-09 Univ Southampton Adjuvants for use in vaccines
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
US7291626B1 (en) * 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
US6867216B1 (en) 1998-04-09 2005-03-15 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signal pathways, compositions and uses related thereto
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU2005201269C1 (en) * 1999-01-13 2008-09-04 Curis, Inc. Regulators of the PCT or smoothened pathway, compositions and uses related thereto
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPP968699A0 (en) * 1999-04-09 1999-05-06 Cura Nominees Pty Ltd Therapeutic compositions and method for their preparation
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
EP1235851B1 (de) 1999-10-13 2006-05-31 Johns Hopkins University School of Medicine Verbindungen zur regulierung des hedgehog-signalwegs, zusammensetzungen und verwendungen davon
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
EP1278763B1 (de) 2000-04-28 2007-02-14 Inflazyme Pharmaceuticals, Ltd. 3-stickstoff-6,7-dioxygenierte steroid verbindungen und verwendungen davon
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
EP1421100B1 (de) * 2001-08-21 2008-07-09 GlycoMed Sciences Limited Chemische synthese von solamargin
ATE312118T1 (de) 2001-09-28 2005-12-15 Glycomed Sciences Ltd Lösungsmittelextraktionsverfahren
WO2003030915A1 (en) * 2001-10-09 2003-04-17 Glycomed Sciences Limited Use of solamargine for treating skin tumors
WO2003030884A2 (en) * 2001-10-09 2003-04-17 Glycomed Sciences Limited Use of solasonine for the treatment of skin tumors
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US6984725B2 (en) * 2002-06-28 2006-01-10 Solbec Pharmaceuticals Ltd. Method for the separation of triglycoalkaloids
AUPS329002A0 (en) * 2002-07-01 2002-07-18 Solbec Pharmaceuticals Limited Glycoalkaloid compositions and various uses thereof
AU2003900194A0 (en) * 2003-01-15 2003-01-30 Solbec Pharmaceuticals Limited Methods of modulating il-6
TWI300352B (en) * 2003-06-05 2008-09-01 G & E Herbal Biotechnology Co Ltd Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
CN1329038C (zh) * 2003-06-20 2007-08-01 德英生物科技股份有限公司 茄属植物的水溶性萃取物、其制备方法及其药学组合物
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20070149491A1 (en) * 2005-05-17 2007-06-28 Findeis Mark A Compounds useful for treating neurodegenerative disorders
US7851641B2 (en) * 2005-05-17 2010-12-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
US8263755B2 (en) * 2006-11-20 2012-09-11 Satori Pharmaceuticals, Inc. Synthesis of compounds useful as modulators of amyloid-beta production
WO2008130449A2 (en) * 2006-11-20 2008-10-30 Satori Pharmaceuticals, Inc. Modulators of amyloid-beta production
ES2842201T3 (es) 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh Inhibidor de HER3 para modulación de radiosensibilidad

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR943800A (fr) * 1946-12-31 1949-03-17 Perfectionnements aux projecteurs cinématographiques utilisant des films de format réduit
ES359406A1 (es) * 1967-10-23 1970-06-01 Erba Carlo Spa Procedimiento para la preparacion de nuevos derivados de (25r)-3 beta-amino-5alfa, 22alfa-espirostano.
DE1900060A1 (de) * 1969-01-02 1970-08-13 Lentia Gmbh Verfahren zur Herstellung von Androstanderivaten
GB1380253A (en) * 1971-01-21 1975-01-08 Inverni Della Beffa Spa Prosapogenins
DE2519261C3 (de) * 1975-04-30 1979-03-01 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verfahren zur Gewinnung des in den Wurzeln und Rhizomen von Helleborus-Arten enthaltenen Hauptsapogenins
NZ193564A (en) * 1979-05-02 1985-01-31 Aruba Pty Ltd Steroid alkaloids from solanum sodomeum and pharmaceutical compositions
US4937182A (en) * 1985-12-19 1990-06-26 Peralta Cancer Research Institute Method for predicting chemosensitivity of anti-cancer drugs
GB2192185B (en) * 1986-07-03 1991-01-16 Genetic Systems Corp Monoclonal antibodies to pseudomonas aeruginosa flagella
US5227160A (en) * 1988-07-15 1993-07-13 The Biomembrane Institute Monoclonal antibody nuh2 capable of inactivating motility of human sperm, antigen defined by said monoclonal antibody and methods of using said monoclonal antibody and antigen
US5766632A (en) * 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception

Also Published As

Publication number Publication date
EP0515386B1 (de) 1999-12-22
BR9105952A (pt) 1992-11-17
EP0515386A1 (de) 1992-12-02
US5958770A (en) 1999-09-28
CA2073855A1 (en) 1991-07-19
AU7159491A (en) 1991-08-05
SG50585A1 (en) 1998-07-20
DE69131861T2 (de) 2000-05-18
JP3168542B2 (ja) 2001-05-21
KR927003842A (ko) 1992-12-18
JPH05503847A (ja) 1993-06-24
EP0515386A4 (en) 1993-10-27
DE69131861D1 (de) 2000-01-27
CA2073855C (en) 2007-04-24
AU654474B2 (en) 1994-11-10
KR100213805B1 (en) 1999-08-02
WO1991010743A1 (en) 1991-07-25

Similar Documents

Publication Publication Date Title
ATE188036T1 (de) Glykoalkaloide
TR199802572T2 (xx) V�cut a��rl���n� ayarlamada elveri�li bile�ikleri tesbit i�in tarama y�ntemleri.
TR199800518T1 (xx) Se�imli beta3 adrenerjik agonistler.
FI20085256A7 (fi) Retrovirusperäisten proteaasi-inhibiittoreiden yhdistelmä
ATE215992T1 (de) Isolierung fötaler erythrozyten
AU541099B2 (en) Detection of occult human blood
MY108526A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
ATE125362T1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
ES2045216T3 (es) Inmunoensayo y derivados polimeros de igg para la compensacion de factores de perturbacion en el inmunoensayo.
AU1130392A (en) Synthetic htlv-iii peptides, compositions and uses thereof
CA2224003A1 (en) Fluorescence resonance energy transfer screening assay for the identification of hiv-1 envelope glycoprotein-medicated cell
NO883505D0 (no) Fremgangsmaate for analyse av fluidums-innstroemning i oljebroenner.
Horne et al. Detection of pregnancy specific beta1-glycoprotein in formalin-fixed tissues.
IT8719331A0 (it) Mandrino per il fissaggio di cella per la centrifugazione del sangue, e simili.
ATE151882T1 (de) Karzinomverwandtes haptoglobin (hpr)
ATE33649T1 (de) Gegen magengeschwuer wirkende 2-guanidino-4-(2substituierte-amino-4-imidazolyl)thiazole und verfahren zu deren herstellung.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
SE436751B (sv) Forfarande enligt krav 1 i patentet 7613920-3 (publ.nr 423903) for framstellning av 17alfa-acyloxi-9alfa, 21-dihalogen-11beta-hydroxi-6alfa-fluor-16beta-metyl-pregna-1,4-dien-3,20-dion-foreningar
DE69624782D1 (de) Elektrodenzuleitung für implantierbare medizinische Vorrichtung, insbesondere für Herzschrittmacher
AU2087495A (en) Means for treating autoimmune diseases and a method for the treatment thereof
KR910006478A (ko) 인체 트립타제 유사 단백질
EP0330924A3 (de) Verwendung von 1,4-Dihydropyridin-Derivaten in der Behandlung von Alkoholsucht
CA2078861A1 (en) Total gonadotropal alpha peptide chain assay
ES2059539T3 (es) Metodo para la prevencion de la enfermedad del injerto frente al huesped.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties